Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. Issue 10 (2nd October 2016) - Assal, Amer; Dong, Baoxia; Khan, Hina; Medavarapu, Ramadevi; Shastri, Aditi; Pradhan, Kith; Friedman, Ellen; Mantzaris, Ioannis; Janakiram, Murali; Battini, Ramakrishna; Kornblum, Noah; Yu, Yiting; et al.